Abstract Insulin-like peptide 5 (INSL5) is a two-chain, three-disulfide bonded member of insulin/relaxin superfamily of peptides that includes insulin, insulin-like growth factor I and II (IGFI and IGFII), insulin-like peptide 3, 4, 5 and 6 (INSL3, 4, 5 and 6), relaxin-1 (H1 relaxin), -2 (H2 relaxin) and -3 (H3 relaxin). Although it is expressed in relatively high levels in the gut, its biological function remains unclear. However, recent reports suggest a significant orexigenic action and a role in the regulation of insulin secretion and b-cell homeostasis, which implies that both agonists and antagonists of the peptide may have significant therapeutic applications. Modern solid phase synthesis techniques together with regioselective disulfide bond formation were employed for a preliminary structurefunction relationship study of mouse INSL5. Two point mutated analogues, mouse INSL5 A-B(R24A, W25A) and mouse INSL5 A-B(K6A, R14A, Y18A) were chemically prepared, where the residues in the B-chain that may be involved in receptor activation and affinity binding, were respectively mutated. Synthetic mouse INSL5 A-B(R24A, W25A) analogue was inactive on RXFP4, the native receptor for INSL5, suggesting Arg B24 and Trp B25 are probably directly involved in INSL5 receptor activation. Mouse INSL5 A-B(K6A, R14A, Y18A) analogue had both decreased affinity and potency on RXFP4 (pIC 50 7.7 ± 0.2, pEC 50 7.87 ± 0.18) which indicated that one or more of these residues are critical for the binding to the receptor.
Introduction
Insulin-like peptide 5 (INSL5) is a peptide hormone of the insulin superfamily that comprises insulin, insulin-like growth factors I and II (IGFI-II), relaxins 1-3 and insulinlike peptides 3-6 ). It was first identified in 1999 from the screening of expressed sequence tags databases (ETS) (Conklin et al. 1999) and it contains all the common/characteristic features of the peptides of the insulin superfamily: it is constituted by two chains, A-and B-chain, it has the conserved cysteine motif whereby two interchain disulfide bonds take place between the A-and the B-chain and one is intramolecular within the A-chain (Conklin et al. 1999) .
In 2005, INSL5 was identified as the specific agonist for the G-protein coupled receptor GPCR142 (Liu et al. 2005) now referred to as relaxin family peptide receptor 4 (RXFP4) according to recent nomenclature (Bathgate et al. 2006) . INSL5 and RXFP4 are found to be expressed in the same tissues such as colon, prostate, kidney, placenta and other peripheral tissues (Conklin et al. 1999 , Liu et al. 2005 , Liu and Lovenberg 2008 with the highest level in the colon (Liu et al. 2005) . Though physiological role of INSL5 is not yet clear, this expression pattern of both INSL5 and its cognate RXFP4 receptor lead to the proposition that INSL5 plays an active role in the stimulation of appetite and in colon motility (Takeda cambridge limited 2009). The results from most recent study suggest that INSL5 is involved in the regulation of insulin secretion and b-cell homeostasis (Burnicka-Turek et al. 2012 ). INSL5 and its agonists have therefore the potential to become therapeutics for the management of eating disorders and/or diabetes. Conversely, an INSL5 antagonist would possess the potential to treat obesity either alone or in conjunction with other known feeding regulators.
To better understand the physiological role of INSL5, prior knowledge of the interaction between the peptide and its cognate receptor at a molecular level is necessary. This can be achieved via the design and chemical synthesis of point-mutated analogues to identify the residues within the peptide responsible for the binding to the receptor and its subsequent activation of downstream intracellular pathways. In theory, such studies are technically easier than studies using mutagenesis of the much larger, more complicated, membrane-bound RXFP4 receptor to determine the molecular interactions that take place between the peptide and receptor.
INSL5 is the most recent member of the insulin/relaxin superfamily for which its receptor has been identified and limited information is currently available regarding its mechanism of interaction with RXFP4 receptor (Belgi et al. 2011 , Luo et al. 2010 . Given the complexity of INSL5 ligand, sequential mutation of the residues from one terminus to the other of each A-and B-chain is achievable but also arduous given the enormous synthesis work that would be required. Such studies may be somewhat simplified by the use of assumptions based on prior studies of a related ligand/receptor pair that has been well-characterized and that is thought to interact on a similar fashion. In this respect, the relaxin-3/RXFP3 system has been very well characterised by us and our collaborators at Johnson & Johnson Pharmaceuticals (USA). Relaxin-3 and INSL5 are closely related as they belong to the same branch in the phylogenetic tree of the relaxin family and their cognate receptors, RXFP3 and RXFP4 respectively, belong to the same class of G-protein coupled receptors (Bathgate et al. 2006) . INSL5 is therefore assumed to interact with RXFP4 receptor in a similar fashion to relaxin-3 binding to and activation of RXFP3 receptor (Haugaard-Jönsson et al. 2009 ).
The residues within relaxin-3 involved in the binding and activation of RXFP3 have largely been identified and they are all within relaxin-3 B-chain (Kuei et al. 2007 ). Moreover, all but one of these same residues are also used by relaxin-3 to bind to and activate RXFP4 receptor ( Fig. 1 ) (Kuei et al. 2007 ). The corresponding residues within mouse INSL5 B-chain were identified and two preliminary analogues, analogue 1 and analogue 2, have been designed and synthesized. We wanted to assess if for INSL5 too these residues are important for RXFP4 binding and the activation. The preliminary results indicate that INSL5 uses a mechanism similar to relaxin-3 with the C-terminal residues, Arg B24 and Trp
B25
, important for activity and residues within the B-chain exposed in the a-helical part involved in the binding interaction with the receptor.
Materials and Methods

Materials
9-fluorenylmethoxycarbonyl (Fmoc) protected L-a-amino acids and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HBTU) were purchased from GL Biochem (Shanghai, China) . N,N-dimethylformamide (DMF), piperidine and trifluoroacetic acid (TFA) were obtained from Auspep (Melbourne, Australia). Fmoc-PAL-PEG-PS and Fmoc-L-Ala-PEG-PS resins with substitution of ca. 0.20 mmol/g were purchased from Applied Biosystems Inc, (Melbourne, Australia), Fmoc-Cys(Acm)-S PHB TentaGel was purchased from Rapp Polymere Fig. 1 Primary structures of synthetic mouse INSL5 analogues. From top to bottom: (top) relaxin-3 sequence where the residues within the B-chain that were found to be important for binding and activation are highlighted in grey for RXFP3 and in black for RXFP4. Plain arrows indicate residues important for the binding and bold arrows the one involved in activation (Kuei et al. 2007 ). (Middle) mouse INSL5 sequence with arrows indicating the corresponding residues within the B-chain that in relaxin-3 were found important for interaction with RXFP4; and (bottom) sequences of the two point mutated analogues designed: mouse INSL5 A-B(R24A, W25A) (analogue 1) and mouse INSL5 A-B(K6A, R14A, Y18A) (analogue 2) (Tübingen, Germany). Acetonitrile, dichloromethane, diethyl ether, and methanol, were from Merck (Melbourne, Australia), and 2-pyridyl disulfide (DPDS) was purchased from Fluka (Buchs, Switzerland). Na 2 HPO 4 and MgSO 4 were purchased from BDH Chemicals (Sydney, Australia). KH 2 PO 4 and MnCl 2 were purchased from AJAX Chemicals (Sydney, Australia). CaCl 2 was purchased from Mallinckrodt (Melbourne, Australia). Dulbecco's Modified Eagle Medium/Nutrient Mixture F-12 (DMEM/F12), L-glutamine, penicillin/streptomycin and foetal bovine serum were all purchased from Invitrogen (Melbourne, Australia). Chlorophenol red b-D galactopyranoside was purchased from Roche (Mannheim, Germany). Diethylene triamine pentaacetic acid (DTPA)-tetra (tBu ester) was purchased from Macrocyclics (Dallas, Texas, US). All other reagents were from Sigma-Aldrich (Sydney, Australia).
Methods
Preparation of Resin-Bound Base Labile Handle-Linked Solubilizing Tagged Peptide
Fmoc-PAL-PEG-PS (0.2 mmol) was N a -deprotected and then carried through five cycles of acylation with FmocLys(Boc)-OH and N a -deprotection as described below. The base labile linker, 4-hydroxymethylbenzoic acid (4 equivalents), was attached via a 1 h acylation using 4 equivalents of HBTU and 6 equivalents of diisopropylethylamine (DIEA). The C-terminal residue was attached to the resin-bound linker via a double 1 h acylation with the Fmoc-amino acid symmetrical anhydride (5 equivalents) in the presence of 0.1 equivalents of catalyst, 4-dimethylamino pyridine (DMAP).
Peptide Synthesis The peptides were solid phase synthesized employing Fmoc-chemistry on one of the following instruments: CEM Liberty TM microwave peptide synthesizer (Ai Scientific, Queensland, Australia), or Protein Technologies Tribute batch-wise peptide synthesizer (Tucson, AZ, USA). The side chain-protecting groups of trifunctional amino acids were TFA-labile, except for tertbutyl (tBu)-protected and acetamidomethyl (Acm)-protected cysteine Cys in the A-chain and Cys(Acm) in the B-chain. The peptides were synthesized on a either 0.1 or 0.2 mmol scale using instrument default protocols with either a 4-or 5-fold molar excess of Fmoc-protected amino acids (0.4 or 0.5 mmol for a 0.1 mmol scale; 0.8 or 1.0 mmol for a 0.2 mmol scale) that were activated by using 4-or 5-fold excess of HBTU in the presence of DIEA (10 equivalents). N a -Fmoc protecting groups were removed by treating the resin-attached peptide with piperidine (20 % v/v) in DMF. Using the microwave synthesizer, the coupling and deprotection were carried out at 75°C using 25 watt microwave power for 5 min and 60 watt microwave power for 3 min respectively. For batch synthesis (on the Tribute) the coupling and deprotection were carried out for 30 and 10 min respectively.
Following the cleavage and purification, as described below, the individual A-and B-chains were combined to give the target two-chain peptides with the cystine framework following the regioselective disulfide bond formation strategy previously described . Briefly, the crude [Cys7,12 (S-thiol), Cys8 (tBu), Cys21 (Acm)] A-chain was oxidised with 2-pyridyl disulfide (DPDS) (solution 4 mM in methanol) to form the intramolecular disulfide bond Cys7-Cys12. Following isolation via RP-HPLC, the oxidised A-chain was treated with DPDS in trifluoromethanesulfonic acid/TFA (1/4 v/v) to convert Cys8 (tBu) into the more reactive pyridinyl group (Cys8(Pyr)). The A-chain was then combined with the B-chain and the intermolecular disulfide bond CysA8-CysB8 was formed. The A-B peptide [Cys21A(Acm)/ Cys20B(Acm)] obtained was then treated with iodine (20 mM solution in acetic acid) to simultaneously cleave the Acm protecting groups and form the last disulfide bond CysA20-CysB20.
Peptide-Resin Cleavage On completion of solid phase synthesis, the peptides were cleaved from the solid support by treatment with trifluoroacetic acid (TFA) containing anisole: triisopropylsilane (TIPS): 3, 6-dioxa-1, 8-octanedithiol (DODT): H 2 O (93 % : 2.5 % : 2 % : 1.5 % : 1 %, 20 ml) for 2 h. The cleaved products were precipitated in ice-cold diethyl ether and centrifuged at 3,000 rpm for 3 min. The pellets were washed by re-suspending them in ice-cold diethyl ether and centrifuging them again. This washing process was repeated at least three times.
Peptide Purification All the HPLC purifications and analytical reaction monitoring, were performed using a Vydac C18 column, either analytical or preparative (4.6 9 250 mm or 22 9 250 mm respectively), in a gradient mode with eluant A: 0.1 % aq. TFA and eluant B: 0.1 % TFA in acetonitrile.
General Procedure for the Cleavage of the Solubilising Tag from Target Peptide To the purified synthetic solubilising tag-linked peptides was added 1 mL of ice cold 0.1 M NaOH. The whole was stirred for 2-5 min after which the pH was made acidic by the addition of 0.1 % aq. TFA. The solution was then applied directly onto a RP-HPLC column for purification as described above.
Peptide Characterization
Matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) was carried out on a Bruker Ultraflex II instrument (Bruker Daltonics, Bremen, Germany) and used to characterize the peptides at each intermediate step using sinapinic acid (3,5-dimethoxy-4-hydroxycinnamic acid) as matrix. The matrix was made up in 70 % acetonitrile containing 0.1 % TFA.
The peptide content was determined using vapor-phase acid hydrolysis in 6 M HCl containing 2 % phenol at 110°C for 24 h. The individual amino acids were converted to stable, fluorescent derivatives using Waters AccQ.Tag kit (Waters, Sydney, Australia). The derivatized amino acids were separated using a Shim-Pak XR-ODS (3 9 75 mm, 2.2 lm) column on Shimadzu RP-HPLC system (Shimadzu, Victoria, Australia).
Functional Assays
Binding Assays Chinese hamster ovary CHO-K1 cells transfected with human RXFP4 were plated out at 50,000 cells per well per 200 lL in a 96 well ViewPlate with clear bottom and white walls precoated with poly-L-lysine. Competition binding experiments were performed with 5 nM of europium-labelled Eu(A)-mouse INSL5 acid (Belgi et al. 2011) in the presence of increasing amounts of peptides following the protocol described previously . GraphPad PRISM 5 (GraphPad Inc., San Diego, USA) was used to analyse the receptorbinding assays data that are expressed as mean ± SEM.
Agonist Assays The peptides were tested for their ability to inhibit cAMP activity in CHO-K1 cells co-transfected with human RXFP4 and a pCRE (cAMP Response Element) b-galactosidase reporter plasmid. On day 1 the cells were plated out in a Corning cell bind 96 well plate at 8,000 per well per 100 lL. A transfection with a poly-CRE (cAMP Response Element) b-galactosidase reporter plasmid was carried out on day 2 and on day 3 the cells were stimulated with 1 lM of forskolin and incubated with increasing concentrations of each peptide as previously described (Liu et al. 2001a , Liu et al. 2001b . In brief, cell culture medium was removed from the plate and the cells were stimulated by the addition of cell culture medium additioned with 1 lM of forskolin and increasing concentrations of the peptides being tested (0.1 nM-1 lM at 10 fold increments). Measurements were made in triplicate wells (100 lL per well) and the plate was incubated for 6 h at 37°C in a humified atmosphere of 5 % CO 2 . After the incubation, the plate was removed from the incubator, the medium aspirated and the plate was frozen at -80°C overnight to assist in cell lysis. The cAMP concentration is assessed with a b-galactosidase colorimetric assay measuring absorbance at 570 nm on Benchmark Plus microplate spectrophotometer (BIO RAD) as previously described (Liu et al. 2001a , Liu et al. 2001b , Scott et al. 2006 . Briefly, the cells were lysed with the addition of 0.19 assay buffer A (100 mM Na 2 HPO 4 , pH 8, 2 mM MgSO 4 , 0.1 mM MnCl 2 ; 25 lL per well) and incubated for 10 min at room temperature. Cells were further incubated for 10 min at room temperature with 19 assay buffer B (assay buffer A containing 0.5 % of TritonX-100 and 40 mM b-mercaptoethanol; 100 lL per well). The colour is developed with the enzyme substrate solution chlorophenolred b-D galactopyranoside (CPRG) (1 mg/mL; 25 lL per well) and quantitated monitoring absorbance at 570 nm on a plate reader. Each concentration point was measured in triplicate and each experiment was performed independently for a total of three times. GraphPad PRISM 5 (GrapdPad Inc., San Diego, USA) was used to analyse the cAMP inhibition assays data that are expressed as mean ± SEM.
Results and Discussion
Two point-mutated analogues have been designed and synthesized in the study. In analogue 1, the pair Arg B24 -Trp B25 expected to be responsible for activation was mutated with Ala to generate mouse INSL5 B(R24A, W25A)-chain and in analogue 2, Lys B6 , Arg B14 and Tyr B18 , within the B chain, expected to be responsible for receptor affinity were also mutated to Ala to give mouse INSL5 B(K6A, R14A, Y18A)-chain. Both B-chain analogues were then combined with the A-chain to give the two chaindisulfide linked peptides. The residue Val B13 in mouse INSL5 B-chain, which corresponds to Ile B15 in relaxin-3 B-chain, was not mutated to Ala as this would only change the size of the side chain whereas for Lys B6 , Arg B14 and Tyr B18 the mutation substantially affects both the side chain charge and the size. On the basis of the results of the bioassays for this analogue, especially the competition binding, the role of these residues can be determined and if necessary further analogues involving a mutation of Val B13 can be designed to investigate the importance (or contribution) of this residue. More generally, poly-mutations were inserted into both the analogues with the purpose to obtain a loss of function in the activation for mouse INSL5 A-B(R24A, W25A) (analogue 1) and in the affinity for mouse INSL5 A-B(K6A, R14A, Y18A) (analogue 2) respectively. If such loss of function is observed after performing the functional assays, the design and synthesis of analogues bearing a single mutation will be required to assess whether individual residues are responsible for the effects observed or two or more of them are acting synergistically.
Given the beneficial effects of the penta-lysine solubilising tag on both the solid phase assembly and the RP-HPLC purification for mouse INSL5 acid as described previously (Belgi et al. 2011 ) and firstly applied, as a proof-of-concept, to the case of human insulin glargine A-chain ), this approach was applied to the B-chain of analogue 1 as well. As for mouse INSL5 B-chain-solubilising tail, the synthesis of analogue 1 B-chain with the penta-lysine tag at the C-terminus led to a crude chromatographic profile with the major peak identified by MALDI-TOF MS as being the target B-chain (Fig. 2a) . This supported the hypothesis of the tag as a spacer that prevents or minimizes the aggregation of the growing chain on the solid support during the synthesis. The following purification by preparative HPLC was straightforward and the partially purified B-chain (Fig. 2b ) was obtained in a good amount (about 26 mg) confirming the positive effect of the polycationic tag in increasing the hydrophilicity of the peptide. The partially purified analogue 1 B-chain with the solubilising tail was then combined with the A-chain. The chain combination and disulfide bond formation were successful and yielded 1.2 mg of the two-chain, three disulfide-linked peptide with the B-chain C-terminally bearing the penta-lysine tail in good yield, 12.9 % calculated on the B-chain, and purity as shown in Fig. 2c . However, upon removal of the tail with a basic treatment (0.1 N NaOH) as specified in the General Methods, the final two-chain analogue was obtained in poor overall yield (0.6 % calculated on the B-chain) leading to the major loss of the peptide and formation of side products as showed in Fig. 2d . It appears that, unexpectedly, tail cleavage seems to be another ''high risk'' reaction in addition to iodine oxidation which is considered to be the crucial step due to the harshness of the reagents used. After the positive application of the NaOH treatment to, first, glargine and then mouse INSL5, this was the first case of a poor outcome leading to the high loss of the final target peptide. The three major peaks eluting at 19.96, 21.63 and 23.04 min respectively were analysed by MALDI-TOF MS. The peak at 19.96 min was identified as the target analogue 1 whereas the other two peaks had lower molecular weight indicating they were generated by fragmentation of the target peptide. However, the nature of the fragments could not be identified. Only the central fraction of the peak at 19.96 min was used to ensure the purity of the analogue, which was confirmed by the mass spectrum (Fig. 2e) . It was freeze dried to give 9.0 lg of effective peptide following amino acid analysis. The 9.0 lg of final peptide were then used for the in vitro characterization. Unfortunately, due to such a small amount of effective peptide, full functional testing with three independent assay replicates could not be performed. The competition binding assay, in fact, was performed only once and although it demonstrated no binding in the concentration range tested (0.01 nM-1 lM), it would need to be repeated at least twice more to be certain of the results. If this result is reproducible, then this would be in contrast to the H3/RXFP3 system where mutations of C-teminal Trp and Arg in the B chain demonstrated full binding with no activity. Nevertheless the cAMP agonism assay of analogue 1 on CHO-K1/RXFP4 cells, which was of most interest for this analogue, was successfully achieved in three independent assays. The analogue, up to a concentration of 1 lM, showed no ability to activate the receptor which was as expected (Fig. 3a) . This was the first evidence that INSL5 is activating RXFP4 receptor with the B-chain via a major contribution from C-terminal Arg and Trp like relaxin-3 does on RXFP3 and RXFP4 which correlates with the mechanism of action proposed for relaxin-3 where the peptide uses the residues exposed in the a-helical region of the B-chain to bind to the receptor, after which the C-terminus of the peptide is in the optimal position for receptor activation (Kuei et al. 2007) . Following the earlier finding that INSL5 requires a C-termini acid for full activity on RXFP4 (Belgi et al. 2011) , the B-chain not only needs to be in the acid form but the terminal two residues need to be Arg and Trp as their Ala mutation suppressed the activity of the peptide completely. However, further studies are required to investigate the individual role of the two residues in the activation, i.e. whether only Trp is important or Arg is also contributing to the overall activity. At the time of the synthesis of analogue 1, a re-assessment of the unsuccessful tail cleavage was carried out. We Fig. 3 In vitro RXFP4 receptor bioassays: a cAMP inhibition assay of analogue 1, analogue 2 and mouse INSL5 acid; b competition binding curve of analogue 2 and mouse INSL5 acid competing with 5 nM of Eu-(A) mouse INSL5 acid. The data are the result of n = 3 independent experiments and are expressed as mean ± SEM decided to change the order of the reactions in the protocol such that the cleavage of the tail was carried out before the iodine oxidation step to form the last disulfide bond. This new order was applied to the synthesis of an analogue of human glargine A(0)R glargine, however, no significant difference in final yield, relative to the B-chain, was observed compared with cleaving the tail as last step before obtaining the final peptide (Kwak et al. 2010 ). The base treatment was shortened to 2 min as a maximum instead of the 2-5 min as indicated above in the Methods and used for human glargine and mouse INSL5 acid (Belgi et al. 2011 ) and the reaction mixture (or peptide solution) after the ice cold base addition was kept at below 0°C. The treatment with NaOH at a lower concentration, 0.01 M, was also investigated but after 20 min treatment it was found to be not as effective as 0.1 M NaOH solution (data not shown). To summarize, a change in the order of the reaction, with the tail cleavage before the formation of the third disulfide bond instead as the last step, is possible and does not generally affect the overall yields which remain similar (Kwak et al. 2010) ; the optimal conditions found were a shortened treatment time of 2 min, instead of a maximum of 5 min, and for the reaction mix to be kept on ice upon the addition of ice cold NaOH 0.1 M (Kwak et al. 2010) .
For the synthesis of the modified B-chain of analogue 2 having a C-terminus acid the preloaded resin FmocTrp(Boc)-PAC-PEG-PS was used. Such synthesis was successful giving the target peptide as the major peak, however its purification by preparative RP-HPLC was very challenging due to the very poor solubility of the peptide. The Ala mutation, in fact, substituted positively charged residues with a non-charged residue giving a B-chain analogue with an overall charge of 0 compared to an overall charge of ?2 for the native sequence of mouse INSL5 B-chain acid. The recovery of partially pure B-chain analogue from the HPLC column was very poor so the synthesis needed to be repeated three times in total to ensure a sufficient amount of B-chain for the combination with the A-chain and formation of the final two-chain peptide. The solubilising tail approach remains undoubtedly a very valuable tool for the synthesis and especially for the post synthesis handling of hydrophobic peptides but its cleavage can be detrimental to some sensitive sequences such as in the case of analogue 1.
Analogue 2 was obtained in sufficient amount to allow a complete in vitro characterisation via the competition binding and the cAMP agonism assays. The peptide was able to inhibit forskolin-stimulated cAMP and hence to activate RXFP4 as a full agonist but with less potency compared to native mouse INSL5 acid with the curve shifted towards the right and a pEC 50 value of 7.87 ± 0.18 versus pEC 50 9.29 ± 0.09 for mouse INSL5 acid (Fig. 3a , Table 1 ).
The relative affinity of analogue 2 competing for binding to RXFP4 with the developed Eu-(A) mouse INSL5 acid (Belgi et al. 2011 ) is shown in Fig. 3b . The analogue had a measured affinity, expressed as pIC 50 ± SEM, of 7.72 ± 0.2 and showed partial binding as if it were able to compete for one binding site but not for a second one. As shown in Fig. 3b , the curve associated with the analogue did not reach zero showing its inability to fully compete with the labelled peptide. This result highlights simultaneously the importance of not only Lys B6 , Arg B14 and Tyr B18 but also of Val B13 which was not mutated. It is, in fact, possible that the affinity of the analogue for the Data are expressed as mean ± SEM of n = 3 independent experiments ND not determined, NA not active in the concentration range tested, Emax (%) efficacy maximum of the peptide in the cAMP assay relative to forskolin as 100 % a partial binding, see Fig. 3b receptor is due to the presence of Val B13 and therefore due to hydrophobic interactions between its side chain and the receptor. The decreased potency in the cAMP agonism assay correlates with the decreased binding affinity suggesting that Lys B6 , Arg B14 and Tyr B18 contribute to both binding and activation even though their contribution in the activation is marginal (or moderate) compared to Arg B24 and Trp B25 whose mutation completely abolishes the activation. The diminished potency can also be a consequence of the non efficient interaction of the peptide with the receptor and therefore the peptide is failing to present Arg B24 and Trp B25 in the optimal position for activation which, once again, is in line with the mechanism of action suggested for relaxin-3 (Kuei et al. 2007 ).
To gain a better understanding of INSL5 structurefunction relationship, the next candidate that needs to be investigated is Val B13 which correspond to Ile 15 in relaxin-3 B-chain and which in this preliminary screening was not mutated to Ala. It was in fact thought that the Val to Ala mutation only affects the size of the side chain whereas for Lys B6 , Arg B14 and Tyr B18 the mutation was substantially changing the charge/polarity and size of the side chains. Therefore it is possible that Val B13 is contributing to INSL5 binding to the receptor with hydrophobic interaction similar to Ile 15 in relaxin-3. Ile 15 in relaxin-3 was mutated to either Gly, Ala or Val and it was observed an increased affinity associated with the analogue with increased side chain length confirming the presence of an hydrophobic interaction between the side chain of the residue and an hydrophobic pocket within the receptor (Kuei et al. 2007 ). To further investigate this hydrophobic interaction, Val B13 should be substituted with a charged amino acid such as Lys having a positive charge or the negatively charged Asp (Schwartz et al. 1987 ) and the effect of these substitutions on the binding tested.
Concluding Remarks
The chemical syntheses of analogues 1 and 2, especially the different approaches applied to the B-chain, highlighted the challenges and difficulties associated with the assembly of this insulin superfamily member. Not only the synthesis of the peptide chains has complications but, and foremost, their purification via HPLC is very difficult due to the extreme hydrophobic properties of INSL5 and its analogues. These same purification issues were encountered in the synthesis of human INSL5 via recombinant techniques (Luo et al. 2010) . This is the first structure-function relationship study of INSL5. The preliminary findings showed that like H3 relaxin, INSL5 peptide uses Arg B24 and Trp B25 residues to activate the receptors and Lys B6 , Arg B14 and Tyr B18 to bind to the receptor. However, it is not conclusive as binding assays for analogue 1 are incomplete. The fact that INSL5 can not activate RXFP3 although it has some affinity, while H3 relaxin has high affinity for RXFP4, suggests that the binding and activation mechanism of INSL5/RXFP4 should be slightly different to that of H3/RXFP3. Further structure-activity studies on INSL5/RXFP4 are required to confirm the binding and activation mechanisms.
